should complete remission, however strictly defined, be the goal for everyone? yes! new york,...
TRANSCRIPT
Should complete remission, however strictly defined, be the goal for everyone? YES!
New York, October 23, 2014Ola Landgren, M.D., Ph.D.Chief, Myeloma ServiceMemorial Sloan-Kettering Cancer Center, New Yorkwww.MSKCC.org
Alternative: be lazy, take it easy
1 2 3 4 5 6“YES ARGUMENTS”
1 2 3 4 5 6“YES ARGUMENTS”
Respect your elders!
Kapoor et al. J Clin Oncol 2013
Importance of good clinical response
1 2 3 4 5 6“YES ARGUMENTS”
Newer myeloma drugs provide better clinical response
Kumar Cancer Treatment Reviews 2010; Korde et al. ASH 2013
CRd
1 2 3 4 5 6“YES ARGUMENTS”
Kapoor et al. J Clin Oncol 2013
Clinical response to therapy impacts progression-free survival
Clinical response to therapy impacts overall survival
Kapoor et al. J Clin Oncol 2013
1 2 3 4 5 6“YES ARGUMENTS”
Quality matters
At diagnosis
Partial response (50% reduction in M protein)
Near complete remission (immunofixation pos only)
Complete remission (immunofixation neg)
1 × 1012
Num
ber o
f mye
lom
a ce
lls
1 × 108
Why stop at CR, when we are not yet done?
CureMRD-
Non-quantitative ASO-PCR of bone marrow
Quantitative ASO-PCR of bone marrow High quality flow cytometry of bone marrowDeep sequencing of bone marrow1 × 104
1 × 106
MRD+
0
Kapoor et al. J Clin Oncol 2013
Clinical response to therapy impacts progression-free survival
Clinical response to therapy impacts overall survival
Kapoor et al. J Clin Oncol 2013
Among CR patients, flow cytometry MRD- impacts survival
Rawstron et al. J Clin Oncol 2013
Rawstron et al. J Clin Oncol 2013
Myeloma genetics and MRD status: impact on overall survival
Hyperdiploidy, t(11;14), or t(6;14)
Gain(1q), del(1p32),t(4;14), t(14;20), t(14;16), or del(17p)
1 2 3 4 5 6“YES ARGUMENTS”
Myeloma is NOT a Polaroid!
Sustained stringent clinical response to therapy impacts overall survival
Kapoor et al. J Clin Oncol 2013
1 2 3 4 5 6“YES ARGUMENTS”
There is already a literature: we are already doing it!
Number of published myeloma MRD studies associated with clinical outcomes
Landgren et al. unpublished data
1
81
1
3
PFS
sCR
Flow
NGS
PET CT
ASO PCR
1
3
1
1
OS
Summary and Conclusions
• Deeper responses in more patients
• Deeper responses = better survival
• Deeper is better, MRD next step forward
Thank you for your attention!
Ola Landgren, M.D, Ph.D.Chief, Myeloma Service
Memorial Sloan-Kettering Cancer Center1275 York Avenue, New York, NY 10065, USA
Email: [email protected] Phone: 212-639-5126